Form 4: Karyopharm Therapeutics Executive Sohanya Cheng Reports Stock Sale to Cover Tax Obligations

Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics, sold 3,445 shares of common stock on March 4, 2025, to cover withholding tax liabilities.

Summary

• Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics Inc., reported a sale of company stock on March 4, 2025.
• The transaction involved the sale of 3,445 shares of common stock at a weighted average price of $6.29.
• The sale was executed under a pre-arranged automatic sale plan adopted on June 7, 2022, to cover withholding tax obligations related to the vesting of restricted stock units.
• Following the transaction, Cheng directly owns 34,314 shares of Karyopharm Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive stock sale for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Executive stock sales are a common occurrence, often related to compensation and tax planning. The use of a pre-arranged trading plan (Rule 10b5-1) is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders due to the increased supply of shares, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Karyopharm Therapeutics, Sohanya Cheng, stock sale, Form 4, insider trading, tax obligations, automatic sale plan, KPTI